Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $58.70 USD
Change Today -0.94 / -1.58%
Volume 800.0K
PCRX On Other Exchanges
As of 5:20 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $121.95
52 Week Low
07/29/15 - $58.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pacira pharmaceuticals inc (PCRX) Related Bloomberg News

View More Bloomberg News

pacira pharmaceuticals inc (PCRX) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (PCRX) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company’s lead product include, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. It also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. The company’s development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical stage for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical phase product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

445 Employees
Last Reported Date: 02/24/15
Founded in 2006

pacira pharmaceuticals inc (PCRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Head of Technical Op...
Total Annual Compensation: $534.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $503.2K
Chief Medical Officer
Total Annual Compensation: $407.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Appoints Scott Braunstein as Senior Vice President to Oversee Strategy and Corporate Development

Pacira Pharmaceuticals, Inc. announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. He will be responsible for evaluating, integrating and optimizing the company’s strategic opportunities for the lead commercial product EXPAREL® (bupivacaine liposome injectable suspension); the company’s hospital-based sales franchise; the DepoFoam®-based internal pipeline product candidates; and external in-licensing and acquisition product candidates. Dr. Braunstein spent 12 years as a healthcare analyst and portfolio manager at J.P. Morgan Asset Management.

Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block

Pacira Pharmaceuticals, Inc. announced that it completed an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) for administration as a nerve block to provide postsurgical analgesia. Pacira requested an End-of-Review meeting in March 2015 following its receipt of a complete response letter (CRL). In April 2015, members of the executive team and regulatory advisors for Pacira participated in the End-of-Review meeting with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products (DAAAP) of the Center for Drug Evaluation and Research. Based upon the FDA guidance that the expected use of EXPAREL will be for a broad spectrum of nerve blocks and not limited to the narrow indication of a single nerve block, Pacira plans to conduct additional Phase 3 studies for upper extremity and lower extremity nerve blocks that together would cover the majority of nerve blocks performed in the U.S. Pacira anticipates working with the FDA to finalize the design of the Phase 3 trials and expects to initiate the studies by the end of 2015.

Pacira Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 10:40 AM

Pacira Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 10:40 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $58.70 USD -0.94

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.44 USD -0.57
Cumberland Pharmaceuticals Inc $6.12 USD -0.05
Durect Corp $2.30 USD -0.19
Halyard Health Inc $41.10 USD +0.32
Teleflex Inc $140.26 USD +1.48
View Industry Companies

Industry Analysis


Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at